MaxCyte, Inc. (MXCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
MXCT POWR Grades
- MXCT scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.93% of US stocks.
- The strongest trend for MXCT is in Value, which has been heading up over the past 177 days.
- MXCT's current lowest rank is in the Momentum metric (where it is better than 10.83% of US stocks).
MXCT Stock Summary
- With a one year PEG ratio of 0.47, MAXCYTE INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- MAXCYTE INC's stock had its IPO on July 30, 2021, making it an older stock than just 2.93% of US equities in our set.
- With a year-over-year growth in debt of 1,300.84%, MAXCYTE INC's debt growth rate surpasses 98.35% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to MAXCYTE INC are VHC, TBLA, VRAY, MKFG, and WRAP.
- To check out MAXCYTE INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001287098.
MXCT Valuation Summary
- In comparison to the median Healthcare stock, MXCT's price/sales ratio is 534.15% higher, now standing at 13.
- Over the past 18 months, MXCT's price/sales ratio has gone down 49.8.
Below are key valuation metrics over time for MXCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MXCT | 2023-01-20 | 13.0 | 2.1 | -23.0 | -21.9 |
| MXCT | 2023-01-19 | 12.6 | 2.1 | -22.4 | -21.3 |
| MXCT | 2023-01-18 | 13.0 | 2.1 | -23.1 | -22.0 |
| MXCT | 2023-01-17 | 13.8 | 2.3 | -24.5 | -23.4 |
| MXCT | 2023-01-13 | 13.3 | 2.2 | -23.7 | -22.6 |
| MXCT | 2023-01-12 | 13.3 | 2.2 | -23.6 | -22.5 |
MXCT Stock Price Chart Interactive Chart >
MXCT Price/Volume Stats
| Current price | $5.70 | 52-week high | $7.76 |
| Prev. close | $5.77 | 52-week low | $3.36 |
| Day low | $5.69 | Volume | 283,400 |
| Day high | $5.86 | Avg. volume | 461,979 |
| 50-day MA | $5.54 | Dividend yield | N/A |
| 200-day MA | $5.51 | Market Cap | 582.71M |
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy ProgramsMaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapiesROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic plat |
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
7 Hot Stocks to Book Profits In Before 2023With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. |
MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the UpgradeMaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
MXCT Price Returns
| 1-mo | 4.40% |
| 3-mo | -15.43% |
| 6-mo | 1.60% |
| 1-year | -11.76% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 4.40% |
| 2022 | -46.42% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...